Trial Profile
Efficacy and Safety of Lanreotide ATG 120 mg in Combination With Temozolomide in Subjects With Progressive Well Differentiated Thoracic Neuroendocrine Tumors. A Phase II, Multicentre, Single Arm, Open-label Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Mar 2023
Price :
$35
*
At a glance
- Drugs Lanreotide (Primary) ; Temozolomide (Primary)
- Indications Bronchial cancer; Carcinoid tumour; Lung cancer; Malignant thymoma; Neuroendocrine tumours
- Focus Therapeutic Use
- Acronyms ATLANT
- Sponsors Ipsen
- 21 Sep 2020 Primary endpoint has been met. (Response of subjects to the study combination therapy)
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress
- 25 Jul 2019 Status changed from active, no longer recruiting to completed.